이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Collecting Data on Retinal Blood Blood Flow and Blood Vessel Shape/Appearance Using an Investigational Device, XyCAM CRE, and to Then Compare Those Images With Images Collected From a Patient's Routine Clinical Examination.

2026년 6월 6일 업데이트: Oday Alsheikh M.D., Stuart Terry Eye Associates

Evaluation of Patients With Retinal Disorders Utilizing the XyCAM CRE Camera.

The primary objective of the XyCAM CRE Camera Study is to evaluate retinal blood flow, choroidal blood flow, and retinal structural features and their association with the progression and characterization of retinal diseases using the XyCAM CRE Camera. The XyCAM CRE is an investigational, noninvasive optical imaging instrument manufactured by Vasoptic Medical, Inc.

XyCAM CRE imaging data will be collected and compared with established retinal imaging modalities currently used in ophthalmic clinical practice, including Color Fundus Photography (CFP), Optical Coherence Tomography (OCT), Optical Coherence Tomography Angiography (OCTA), and Fluorescein Angiography (FA). Imaging data obtained from XyCAM CRE and reference modalities will be assessed to investigate correlations, agreement, and differences between measurements in order to evaluate the potential of XyCAM CRE to provide complementary diagnostic and disease management information in retinal disease.

Secondary objectives of the study include:

Comparing image quality and image-derived information obtained from XyCAM CRE with other clinical reference imaging modalities across different operators and a diverse study population representative of the general population; Investigating the relationship between XyCAM CRE imaging data and established clinical indicators of glaucoma, macular degeneration, hypertensive retinopathy, diabetic retinopathy, inherited retinal disease, and retinal vascular disease.

연구 개요

상태

아직 모집하지 않음

상세 설명

This XyCAM CRE Camera Study is a prospective longitudinal observational cohort imaging study. It is a non-randomized, non-masked, early feasibility study designed to collect retinal imaging data from healthy adults with normal retinal findings and from patients diagnosed with retinal and ocular diseases.

The study will consist of two phases: 1) screening and 2) testing. Patients presenting for routine ophthalmic standard of care evaluations will be screened for eligibility.

Eligible participants will complete four testing visits scheduled approximately 4 months apart (±2 months). At each testing visit, the Principal Investigator (PI) and designated study personnel will document participants' clinical status, obtain intraocular pressure (IOP) and blood pressure (BP) measurements, and acquire repeat XyCAM CRE retinal images. No additional follow-up will be required after completion of Visit 4 procedures.

The XyCAM CRE is an investigational, noninvasive optical imaging system manufactured by Vasoptic Medical, Inc. The device acquires rapid sequential digital retinal images while illuminating the retina with a low-power laser. Proprietary software algorithms analyze the image sequences to estimate retinal blood flow dynamics and generate additional quantitative vascular and structural measurements that may have diagnostic or disease-monitoring value.

The purpose of this study is to investigate the clinical utility of retinal and choroidal blood flow imaging and to evaluate the potential role of XyCAM CRE-derived measurements in the diagnosis and management of ocular disease. Up to 350 participants will be enrolled at Stuart Terry Eye Associates

During study visits, retinal imaging data obtained using XyCAM CRE will be compared with data obtained from established retinal imaging modalities currently used in ophthalmic clinical practice, including Color Fundus Photography (CFP), Optical Coherence Tomography (OCT), Optical Coherence Tomography Angiography (OCTA), and Fluorescein Angiography (FA). The study will utilize:

  1. Laser Speckle Contrast Imaging (LSCI) using the investigational XyCAM CRE system; and
  2. Retrospective and/or clinically acquired reference imaging data from CFP, OCT, OCTA, and FA obtained using standard clinical imaging systems.

LSCI-based retinal blood flow imaging has demonstrated potential as a diagnostic biomarker for assessing disease presence, severity, and progression. Accordingly, LSCI technology implemented in the investigational XyCAM CRE system is the primary imaging modality under evaluation in this study.

XyCAM CRE will be used to obtain retinal blood flow (RBF) measurements from one or more retinal regions. Imaging data will be stored in de-identified form and analyzed to generate region-specific RBF metrics for comparison with participant clinical status and measurements derived from reference imaging modalities.

This study also seeks to establish a broader reference dataset of retinal blood flow measurements obtained from both healthy and diseased eyes. Currently, there is limited widely accepted normative retinal blood flow data available for clinical comparison. Data collected in this study may contribute to future statistical analyses and support the development of reference datasets for subsequent clinical and research applications.

Alterations in retinal perfusion are associated with multiple vision-threatening ocular conditions, including glaucoma, diabetic retinopathy, retinal vein occlusion, and age-related macular degeneration, as well as systemic and neurologic disorders such as cardiovascular disease and cognitive impairment. In addition, intravitreal anti-vascular endothelial growth factor (anti-VEGF) therapy may influence retinal blood flow, suggesting a potential role for retinal perfusion imaging in treatment monitoring and clinical decision-making.

Through longitudinal retinal and choroidal blood flow imaging, this study aims to further characterize the relationship between microvascular perfusion abnormalities and the progression of common retinal diseases.

연구 유형

관찰

등록 (추정된)

350

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

  • 이름: Yvette L Macias, BA in Biology and Chemistry
  • 전화번호: 210-600-0040
  • 이메일: yvettem@lenzaadmin.com

연구 장소

    • Texas
      • San Antonio, Texas, 미국, 78212
        • Stuart Terry Eye Associates
        • 연락하다:

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

  • 성인
  • 고령자

건강한 자원 봉사자를 받아들입니다

예

샘플링 방법

비확률 샘플

연구 인구

Adult patient with or without the presence of Retinal Disease, who meets the Inclusion/Exclusion Criteria.

설명

Inclusion Criteria:

  • The Subject present to the ophthalmology/optometry clinic for eye examination. A signed/dated consent form has been obtained from a Subject who is capable of giving informed consent and compliant with the restrictions and requirements if the protocol.

The Subject is 21 years old with binocular vision.

Exclusion Criteria:

  • The Subject has significant media opacity (eg: a significant corneal scar) The Subject's medical history or health status suggests that the Subject may have an adverse reaction to administration of tropicamide or fluorescein dye.

The Subject has more than 15 dioptors of refractive error. The Subject is less that 21 years of age. The Subject is unable to follow instructions or otherwise unable to complete the study procedures.

The Subject has medical conditions such as nystagmus that will likely prevent the Subject from being able to hold their gaze steady during imaging, reducing the likelihood that high quality data can be acquired from the Subject.

The Subject is pregnant.

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

코호트 및 개입

그룹/코호트
개입 / 치료
Group A, Healthy Subjects
Subjects with no retinal disease present upon examination.
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.
Group B, Subjects with Moderate to Severe Glaucoma
Subjects diagnosed with moderate to severe glaucoma in at least one eye, as determined by the Hodapp-Anderson criteria for glaucomatous visual field loss.
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.
Group C, Glaucoma Suspect or Mild Glaucoma Subjects
Subjects diagnosed as glaucoma suspects or with mild glaucoma in at least one eye based on clinical findings including elevated intraocular pressure (IOP), suspicious optic nerve appearance, borderline or early visual field abnormalities, and/or retinal nerve fiber layer (RNFL) thinning identified by Optical Coherence Tomography (OCT).
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.
Group D, Subjects with AMD
The Subject has been diagnosed with AMD based on clinical diagnostic criteria for AMD
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.
Group E, Subjects with Diabetic Eye Disease
The Subject has been diagnosed via clinical diagnostic guidelines with diabetic eye disease, such as non-proliferative diabetic retinopathy (NPDR), proliferative diabetic retinopathy (PDR), diabetic macular edema (DME), and diabetes without significant ocular pathology visible on fundus examination.
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.
Group F, Subjects with Hypertensive Retinopathy
The Subject has been diagnosed with Hypertensive Retinopathy based on clinical diagnostic criteria for Hypertensive Retinopathy.
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.
Group G, Pilot Subjects with other ocular pathologies and interventions
The Subject is determined by the Principal Investigator to have pathology or has undergone interventions that may significantly reduce or elevate ocular blood flow; and Subjects in this group are recruited on a pilot basis to assess the preliminary (with limited statistical power) promise of RBF monitoring in a diverse set of pathologies.
The investigational XyCAM CRE imaging system will be used to acquire retinal blood flow and structural imaging data. No therapeutic intervention is administered; the device is used for observational imaging and data collection only.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Correlation of XyCAM CRE retinal blood flow measurements with reference retinal imaging modalities in retinal disease
기간: From enrollment through completion of Visit 4 (approximately 12-18 months). Participants will complete four testing visits scheduled approximately 4 months apart (±2 months).
Retinal blood flow (RBF) data will be obtained using XyCAM CRE imaging and compared with retinal imaging modalities currently used as standard of care in ophthalmology, including Color Fundus Photography (CFP), Optical Coherence Tomography (OCT), Optical Coherence Tomography Angiography (OCTA), and Fluorescein Angiography (FA). Measurements obtained from XyCAM CRE and reference imaging modalities will be assessed for correlation, agreement, and differences to evaluate the potential of XyCAM CRE to provide complementary information for the diagnosis and management of retinal disease.
From enrollment through completion of Visit 4 (approximately 12-18 months). Participants will complete four testing visits scheduled approximately 4 months apart (±2 months).

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 6월 15일

기본 완료 (추정된)

2029년 6월 15일

연구 완료 (추정된)

2030년 6월 15일

연구 등록 날짜

최초 제출

2026년 6월 6일

QC 기준을 충족하는 최초 제출

2026년 6월 6일

처음 게시됨 (실제)

2026년 6월 11일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 6월 11일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 6월 6일

마지막으로 확인됨

2026년 5월 1일

추가 정보

이 연구와 관련된 용어

키워드

추가 관련 MeSH 약관

기타 연구 ID 번호

  • 20260857

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

예

미국에서 제조되어 미국에서 수출되는 제품

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다